



李氏大藥廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)
(Stock Code 股份代號:950)

THIRD 第三季度業績報告
QUARTERLY 2022
REPORT

第三季度業績報告

2022

* For identification purpose only
僅供識別

QUARTERLY FINANCIAL STATEMENTS

The directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”) present herewith the unaudited consolidated quarterly financial results (the “**Quarterly Results**”) of the Company and its subsidiaries (collectively, the “**Group**”) for the three months and nine months ended 30 September 2022, together with the comparative figures for the corresponding period in 2021. The Quarterly Results are unaudited, but have been reviewed by the Company’s auditor, HLM CPA Limited (the “**Auditor**”) in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”). The audit committee of the Company has also reviewed with the management and the Auditor the Quarterly Results before recommending it to the board of Directors (the “**Board**”) for approval.

季度財務報表

李氏大藥廠控股有限公司(「**本公司**」)董事(「**董事**」)謹此呈報本公司及其附屬公司(統稱「**本集團**」)截至二零二二年九月三十日止三個月及九個月之未經審核綜合季度財務業績(「**季度業績**」)連同二零二一年同期之比較數字。季度業績未經審核，惟獲本公司核數師恒健會計師行有限公司(「**核數師**」)按照香港會計師公會頒佈之《香港審閱工作準則》第2410號「實體的獨立核數師對中期財務資料的審閱」進行審閱。本公司審核委員會於向董事會推薦季度業績以供批准前，亦已與管理層及核數師審閱季度業績。

BUSINESS REVIEW

There was no major change to the “dynamic-zero” policy in China to contain the outbreak of COVID and the business environment in the region remained tough during the third-quarter 2022. Against the backdrop of a sagging economy in the region, the Group’s revenue growth remained moderate in the quarter under review and delivered a stable performance in the first nine months of the year.

Revenue and Profit

First nine months of 2022 revenue of the Group totalled HK\$1,036,182,000 (First nine months of 2021: HK\$952,387,000), an increase of 8.8% compared to the same period last year. Third-quarter 2022 revenue of the Group totalled HK\$387,016,000 (Third-quarter 2021: HK\$368,335,000), an increase of 5.1% compared to the prior-year quarter and a sequential increase of 19.3% over second-quarter 2022. First nine months of 2022 sales growth was primarily driven by the sales of newly launched Bredinin™ since third-quarter last year which grew by 293.5%, as well as Trepstinil Injection and Yallaferon® which grew by 30.8% and 3.1%, respectively, and offset lower sales of out-patient drugs such as Ferplex® and surgical drugs such as Livaracine® and Slounase®.

Sales of licensed-in products in the first nine months of 2022 accounted for 61.7% (First nine months of 2021: 58.5%) of the Group’s revenue while sales of proprietary and generic products in the first nine months of 2022 contributed 38.3% (First nine months of 2021: 41.5%) of the Group’s revenue.

業務回顧

於二零二二年第三季度，中國為遏止 COVID 疫情而推行的「動態清零」政策並無重大變動，區內營商環境仍然艱難。儘管區內經濟蕭條，惟於回顧季度內，本集團收益維持適度增長，本年度首九個月表現平穩。

收益及溢利

於二零二二年首九個月，本集團錄得總收益 1,036,182,000 港元 (二零二一年首九個月：952,387,000 港元)，較去年同期增長 8.8%。本集團二零二二年第三季度的總收益為 387,016,000 港元 (二零二一年第三季度：368,335,000 港元)，較去年同一季度增長 5.1%，亦較二零二二年第二季度增長 19.3%。二零二二年首九個月的銷售額錄得增長，主要受到自去年第三季度新推出的《布累迪寧》™ 以及曲前列尼爾注射液及《尤靖安》® 貢獻的銷售額 (分別上升 293.5%、30.8% 及 3.1%) 帶動，抵銷了《菲普利》® 等門診藥物以及《立邁青》® 及《速樂涓》® 等外科藥物的銷售額跌幅。

引進產品於二零二二年首九個月的銷售額佔本集團收益 61.7% (二零二一年首九個月：58.5%)，而專利產品及仿製產品於二零二二年首九個月的銷售額則佔本集團收益 38.3% (二零二一年首九個月：41.5%)。

First nine months of 2022 gross profit of the Group was HK\$661,801,000 (First nine months of 2021: HK\$634,796,000), an increase of 4.3% compared to the same period last year. Third-quarter 2022 gross profit of the Group was HK\$242,323,000 (Third-quarter 2021: HK\$248,250,000), a decrease of 2.4% compared to the prior-year quarter. Third-quarter 2022 gross profit margin of the Group was 62.6%, decreased by 4.8 percentage points as compared to 67.4% achieved during the prior-year quarter. The Group's gross profit margin was 63.9% in the first nine months of 2022, decreased by 2.8 percentage points as to 66.7% achieved in the same period last year. The decreased gross profit margin was mainly attributable to the increased purchase price on certain licensed-in products during the quarter under review.

Research and development (“R&D”) expenses represented new drugs development in major therapeutic areas such as cardiovascular, woman health, paediatrics, rare diseases, dermatology and obstetrics, as well as in oncology under a separate R&D arm within the Group. An aggregate of HK\$293,795,000 has been spent in the first nine months of 2022 (First nine months of 2021: HK\$345,218,000), decreased by 14.9% compared to the same period last year and represented 28.4% to the corresponding revenue for the period (First nine months of 2021: 36.2%). Among which HK\$166,853,000 (First nine months of 2021: HK\$180,448,000) has been recognised as expenses and HK\$126,942,000 (First nine months of 2021: HK\$164,770,000) has been capitalised as intangible assets. In addition, the Group has paid a license fee of HK\$7,800,000 in July 2022 for the development, marketing and commercialisation right of Renazorb® and the license fee thereof has been recognised as intangible assets during the first nine months of 2022 (First nine months of 2021: HK\$100,446,000). The Group continues to optimise the resources allocation among prioritised R&D projects and the cost-saving effect thereof has continued to show.

於二零二二年首九個月，本集團錄得毛利661,801,000港元(二零二一年首九個月：634,796,000港元)，較去年同期增長4.3%。本集團二零二二年第三季度的毛利為242,323,000港元(二零二一年第三季度：248,250,000港元)，較去年同期減少2.4%。本集團二零二二年第三季度的毛利率為62.6%，較去年同期同一季度的67.4%下降4.8個百分點。本集團二零二二年首九個月的毛利率為63.9%，較去年同期的66.7%下降2.8個百分點。毛利率率下跌主要由於回顧季度內若干引進產品的採購價上升所致。

研究及開發(「研發」)費用來自心血管、女性健康、兒科、罕見病、皮膚科及產科等各個主要治療領域的新藥開發，以及本集團內的獨立腫瘤科研發分支。本集團於二零二二年首九個月耗資合計293,795,000港元(二零二一年首九個月：345,218,000港元)，較去年同期減少14.9%，且相當於相應期間收益28.4%(二零二一年首九個月：36.2%)，當中166,853,000港元(二零二一年首九個月：180,448,000港元)已確認為費用，而126,942,000港元(二零二一年首九個月：164,770,000港元)已資本化作為無形資產。此外，本集團已於二零二二年七月支付Renazorb®的開發、營銷及商品化權利的專利費7,800,000港元，而相關專利費已於二零二二年首九個月確認為無形資產(二零二一年首九個月：100,446,000港元)。本集團繼續優化各優先研發項目的資源分配，減省成本的效果持續浮現。

The Group's selling and distribution expenses was HK\$269,121,000 in the first nine months of 2022, representing an increase of HK\$10,258,000 or 4.0% compared to HK\$258,863,000 in the same period last year. Overall, the selling expenses to revenue ratio during the first nine months of 2022 was 26.0%, decreased by 1.2 percentage points as to 27.2% same period last year. In March 2022, the Group has launched its own flagship online stores on e-commerce platform of Alibaba.com and JD.com to strengthen its brand awareness and expand its sales channels. The Group continues to deploy adequate resources to support the works for strengthening the distribution channels, preparing for the roll-out of new and upcoming products, as well as transforming the brand of selected products of the Group.

Overall, net profit attributable to the owners of the Company in the first nine months of 2022 was HK\$62,684,000, decreased by 97.1% over the same period in 2021, and was mainly attributable to the net effect of (i) the absence of one-off gain of approximately HK\$2.32 billion attributable to the derecognition of the investment in Zhaoke Ophthalmology Limited as an associate of the Company in April 2021; (ii) the absence of an aggregate one-time loss of approximately HK\$190.1 million attributable to the estimated impairment of intangible assets due to the optimisation of R&D portfolio in the second-quarter 2021; and (iii) the absence of one-time loss of approximately HK\$40.2 million attributable to the full impairment for the licensing fee and development cost for a launched oral antihypertensive product previously capitalised, in the second-quarter 2021.

於二零二二年首九個月，本集團的銷售及分銷費用為269,121,000港元，較去年同期的258,863,000港元增加10,258,000港元或4.0%。整體而言，二零二二年首九個月銷售費用對收益的比率為26.0%，較去年同期的27.2%下降1.2個百分點。於二零二二年三月，本集團已於阿里巴巴及京東商城電子商貿平台推出自家旗艦網店，以加強品牌認知及拓展銷售渠道。本集團亦繼續調撥充足資源支援各項工作，包括強化分銷渠道，為新產品及即將面世的產品上市作準備，以及就本集團的選定產品進行品牌轉型。

整體而言，二零二二年首九個月的本公司擁有人應佔純利為62,684,000港元，較二零二一年同期減少97.1%，主要是源於以下各項的淨影響：(i)缺少因於二零二一年四月終止將於兆科眼科有限公司的投資確認為本公司的聯營公司而錄得的一次性收益約23.2億港元；(ii)缺少因二零二一年第二季度優化研發組合後產生估計無形資產減值而錄得的一次性虧損總計約190,100,000港元；及(iii)缺少二零二一年第二季度因之前就推出口服降壓藥產品撥充資本的專利費及開發成本全數減值而錄得的一次性虧損約40,200,000港元。

Manufacturing Facilities and Production Capability

Over the years, there have been considerable changes and upgrades in the Group's manufacturing and production capability. During the period under review and up to date, the Group's Hefei site has completed the production capacity expansion and process scale up facility upgrades of Yallaferon[®], same line production facility upgrades for new pre-filled syringe injection products before introduction to the market, and the making of registration batch of new product in the form of oral lyophilised powder used as sensitiser in surgery for tumor. In Nansha site, the process scale up equipment installation and commission for the manufacturing of inhaled pharmaceutical aerosols has been completed and will have the process scale up pilot run soon, the production process upgrades for oral dose antihypertension drug is in progress, and the making of three pivotal registration batches of the oral cytotoxic drugs in the special workshop has been completed.

Drug Development

To date, the Group has over 40 projects in its pipeline from early- to late-stage development. The applications made in the prior year for New Drug Application ("NDA") of Adasuve[®], and for Abbreviated New Drug Application ("ANDA"), namely Epinastine Hydrochloride tablet and Apremilast tablet (阿普米司特片), are under review by the Centre for Drug Evaluation (the "CDE").

製造設施及生產能力

多年來，本集團對其製造及生產能力作出多次大規模變動及升級。於回顧期間及截至目前為止，本集團合肥基地已完成《尤靖安》[®]產能提升及工藝放大設施升級，預充式注射液新產品上市前共線設施升級改造，以及用作腫瘤手術顯影劑的口服凍乾粉新劑型產品註冊批次生產。南沙基地生產氣溶膠吸入劑的工藝放大設備已完成安裝與調試，將於短期內進行工藝放大試生產工作，用於口服降壓藥產品的生產工藝升級改造工作進行中，而口服細胞毒性藥物已在專用車間完成三批關鍵註冊批次生產。

藥物開發

截至目前為止，本集團管道中有超過40個分別處於早期至後期開發階段的項目。於過往年度提交的新藥上市申請（「新藥申請」）（Adasuve[®]）及簡化新藥上市申請（「簡化新藥申請」）（即鹽酸依匹斯汀片及阿普米司特片）正由藥品審評中心（「藥審中心」）評審。

Major Therapeutic Areas

The Group is currently developing several assets in major therapeutic areas, such as cardiovascular, woman health, paediatrics, rare diseases, dermatology and obstetrics, which includes late-stage programs such as (1) Cetraxal® Plus for acute otitis externa (AOE) and acute otitis media with tympanostomy tubes (AOMT) which has completed its Phase III clinical trial stage and has filed application to the CDE in October 2022; and (2) Intrarosa® in the treatment of vulvovaginal atrophy (VVA) which is currently in Phase III clinical trial stage and has completed the patient enrolment in October 2022.

Oncology Pipeline

China Oncology Focus Limited (“COF”), a 65% owned subsidiary of the Group, is a clinical development stage company and the Group’s R&D arm focused on oncology with emphasis in immuno-oncology. To date, COF has built a pipeline of 10 oncology assets, including 6 innovative and 4 generics, through internal development and in-licensing, and is currently developing several assets, including (1) Socazolimab (an anti-PD-L1 antibody) in recurrent or metastatic cervical cancer in new drug application stage in China; (2) Socazolimab in osteosarcoma in Phase III clinical trial; (3) Socazolimab combined with chemotherapy in small cell lung cancer in Phase III clinical trial and has completed the patient enrollment in May 2022; (4) Zotiraciclib, an oral multi-kinase inhibitor in Phase I clinical trial for glioblastoma; (5) Gimtecan, a topoisomerase I inhibitor in Phase II clinical trial for ovarian cancer and in Phase Ib/II clinical trial for small cell lung cancer and a Phase I clinical trial for pancreatic cancer in China; and (6) Socazolimab combined with Pexa-vec (oncolytic virus) which is in Phase Ib clinical trial for melanoma.

主要治療領域

本集團現正開發心血管、女性健康、兒科、罕見病、皮膚科及產科等主要治療領域的多項資產，包括處於後期開發階段的計劃，例如(1) Cetraxal® Plus，治療急性外耳道炎及伴有鼓膜置管的急性中耳炎，剛完成第III期臨床試驗階段，並已於二零二二年十月向藥審中心提交申請；及(2) Intrarosa®，用於治療外陰陰道萎縮，目前處於第III期臨床試驗階段，並已於二零二二年十月完成患者入組。

腫瘤管道

由本集團擁有65%權益的附屬公司中國腫瘤醫療有限公司(「COF」)為本集團在腫瘤科方面的研發分支，並為臨床開發階段公司，專研免疫腫瘤療法領域。截至目前為止，COF已通過內部開發及從外引進的方式建立涵蓋10項腫瘤資產的管道，包括6項創新藥及4項仿製藥，現正開發多項資產，包括(1) Socazolimab(抗PD-L1抗體)，於中國處於復發性或轉移性宮頸癌新藥申請階段；(2) Socazolimab骨肉瘤第III期臨床試驗；(3) Socazolimab結合化療的小細胞肺癌第III期臨床試驗，已於二零二二年五月完成患者入組；(4) Zotiraciclib，一種口服多激酶抑制劑，現正進行膠質母細胞瘤第I期臨床試驗；(5) 吉馬替康，一種拓撲異構酶I抑制劑，現正於中國進行卵巢癌第II期臨床試驗、小細胞肺癌第Ib/II期臨床試驗及胰臟癌第I期臨床試驗；及(6) Socazolimab結合Pexa-vec(溶瘤病毒)，現正進行黑色素瘤第Ib期臨床試驗。

During the period under review and up to date, the Group obtained 7 ANDA and Import Drug License (“**IDL**”) approvals from the China’s National Medical Products Administration (“**NMPA**”).

Zingo®

On 1 March 2022, the Drug Registration Certificate for Zingo® (Lidocaine Hydrochloride Powder Intradermal Injection System) has been obtained from the NMPA. Zingo® is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3–18 years of age and to provide topical local analgesia prior to venipuncture in adults. The rapid onset of analgesia in 1–3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure.

INOmax®

On 8 March 2022, the Drug Registration Certificate for INOmax® (nitric oxide gas for inhalation) has been obtained from the NMPA. INOmax® is a therapy for the treatment of hypoxic respiratory failure (“**HRF**”) associated with pulmonary hypertension (“**PPHN**”) in term and near-term infants greater than 34 weeks gestational age. PPHN is a serious condition in which blood vessels in the lungs constrict, making it difficult to oxygenate blood, often resulting in HRF. INOmax® is a vasodilator which selectively relaxes pulmonary blood vessels and, in conjunction with ventilatory support and other appropriate agents, improves oxygenation in this fragile newborn population.

High Concentration Treprostinil Injection

On 9 March 2022, the Drug Registration Certificate for High Concentration Treprostinil Injection (specification: 20ml:50mg) developed and manufactured by Zhaoke Pharmaceutical (Hefei) Company Limited, a wholly-owned subsidiary of the Company, has been obtained from the NMPA.

於回顧期間及截至目前為止，本集團已取得中國國家藥品監督管理局（「**國家藥監局**」）發出7項簡化新藥申請及進口藥品註冊批准。

Zingo®

於二零二二年三月一日，Zingo®（鹽酸利多卡因粉末皮內注射給藥系統）取得國家藥監局的藥品註冊許可證。Zingo®為用於皮膚表層的醃胺局部麻醉劑，用於3至18歲兒童靜脈穿刺或周邊靜脈插管前局部鎮痛，以及成人靜脈穿刺前外用局部鎮痛。Zingo®注射後1–3分鐘即見鎮痛效果，為護理人員及患者提供無痛、無針的注射。

INOmax®

於二零二二年三月八日，INOmax®（一氧化氮吸入性氣體）取得國家藥監局的藥品註冊許可證。INOmax®是一種用於治療患有低氧性呼吸衰竭伴隨肺動脈高壓的足月兒及34週以上早產兒的療法。肺動脈高壓是一種肺血管收縮導致血液難以供氧的嚴重疾病，經常導致低氧性呼吸衰竭。INOmax®是一種血管擴張劑，可選擇性地放鬆肺血管，並通過配合換氣裝置及其他適當藥物，改善脆弱新生兒群體的氧合。

高濃度曲前列尼爾注射液

於二零二二年三月九日，本公司全資附屬公司兆科藥業（合肥）有限公司開發及製造的高濃度曲前列尼爾注射液（規格：20毫升：50毫克）取得國家藥監局的藥品註冊許可證。

Natulan®

On 21 April 2022, the Drug Registration Certificate for Natulan® (Procarbazine Hydrochloride Capsules) has been obtained from the NMPA. Natulan® has been approved for combining with chemotherapy to treat Hodgkin's lymphoma (HL) in adult.

Teglutik®

On 31 May 2022, the Drug Registration Certificate for Teglutik® (Riluzole Oral Suspension) has been obtained from the NMPA. Teglutik® has been approved to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS).

Nadroparin Calcium Injection

On 31 May 2022, the Drug Registration Certificate for Nadroparin Calcium Injection has been obtained from the NMPA.

Azilsartan Tablets

On 20 September 2022, the Drug Registration Certificate for generics of Azilsartan Tablets has been obtained from the NMPA. Azilsartan Tablets has been approved to treat hypertension.

In addition, on 26 October 2022, AU409, an investigational first-in-class compound with oral active in models of hepatocellular carcinoma developed by Auransa Inc. and manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly-owned subsidiary of the Company, has been approved by the United States Food and Drug Administration to conduct clinical trial in patients with advanced primary liver cancers or advanced solid tumor with liver predominant metastatic disease in the United States.

Natulan®

於二零二二年四月二十一日，Natulan®（鹽酸丙卡巴胍膠囊）取得國家藥監局的藥品註冊許可證。Natulan®獲認可用於結合化療醫治成人霍奇金淋巴瘤。

Teglutik®

於二零二二年五月三十一日，Teglutik®（利魯唑口服混懸液）已取得國家藥監局的藥品註冊許可證。Teglutik®獲認可用於延長肌萎縮性脊髓側索硬化症患者的生命或延長其發展至需要機械通氣支持的時間。

那曲肝素鈣注射液

於二零二二年五月三十一日，那曲肝素鈣注射液已取得國家藥監局的藥品註冊許可證。

阿齊沙坦片

於二零二二年九月二十日，阿齊沙坦片仿製藥已取得國家藥監局的藥品註冊許可證。阿齊沙坦片獲批治療高血壓。

此外，於二零二二年十月二十六日，由 Auransa Inc. 開發並由本公司全資附屬公司兆科藥業（廣州）有限公司生產、具有口服活性劑並用於肝細胞癌模型的首創研究性化合物 AU409 已獲美國食品藥品監督管理局批准用於進行臨床試驗，對象為美國的晚期原發性肝癌或晚期實體瘤肝轉移患者。

Business Partnership

In-licensing approach is the Group's preferred mode of business development strategy. Nevertheless, the Group has remained selective in entering new in-licensing deals. On 18 July 2022, the Group has entered into a license agreement with Unicycive Therapeutics, Inc., a NASDAQ-listed company, pursuant to which the Group has been granted exclusive rights to develop, market and commercialise Renazorb® (lanthanum dioxycarbonate) in Mainland China, Hong Kong, and certain other Asian markets. Renazorb® is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.

Corporate Development

On 22 September 2022, the Group has entered into the Equity Transfer Agreement with the purchaser to dispose 100% equity interest in the Guangzhou Zhaokang Hospital Company Limited* (廣州兆康醫院有限公司), an indirect wholly-owned subsidiary of the Company which owns the land use right in the land parcel located at Huangge Da Dao West, Huangge Zhen, Nansha District, Guangzhou, the People's Republic of China specifically for medical and sanitary use, at the consideration of RMB200,000,000 (approximately HK\$226,000,000), details of which has been set out in the announcement of the Company dated 22 September 2022. To date, the transaction is yet to be completed pending fulfillment of the conditions including, among others, the completion of due diligence investigation.

* For identification purpose only

業務夥伴

引進策略為本集團業務發展策略的首選模式。然而，本集團在訂立新的引進交易時，仍然堅持精挑細選。於二零二二年七月十八日，本集團與納斯達克上市公司 Unicycive Therapeutics, Inc. 訂立特許協議，據此，本集團獲授於中國內地、香港及若干其他亞洲市場開發、營銷及商品化生產 Renazorb® (二氧碳酸鏷) 的獨家權利。Renazorb® 是創新磷酸鹽結合劑，開發目的為治療慢性腎病患者的高磷血症。

企業發展

於二零二二年九月二十二日，本集團與買方訂立股權轉讓協議，以出售廣州兆康醫院有限公司(本公司的間接全資附屬公司，擁有位於中華人民共和國廣州南沙區黃閣鎮黃閣大道西的地塊(特別作為醫療衛生用地)的土地使用權)100%股權，代價為人民幣200,000,000元(約226,000,000港元)，詳情載於本公司日期為二零二二年九月二十二日的公佈。截至目前為止，該交易尚未完成，仍有待若干條件達成，其中包括完成盡職調查。

* 僅供識別

PROSPECTS

Towards the end of 2022, the Group remains of the view that the tough environment will be persisted amid uncertainties on various external factors such as COVID pandemic, geopolitical tensions and rising inflation, and foresees that pressure on drug prices will continue to be one of the key challenges to industry players as China is still facing the problem of promoting the growth of its pharmaceutical industry while ensuring affordable and easily accessible drugs for its patient population. The Group will closely monitor the impact thereof and will continue to implement tight cost control and to keep expenditure within the limits of revenue.

The expiration of the licensing agreement of Carnitene[®], which was used to be the flagship product for over a decade, marks the beginning of a new era of the Group. Nevertheless, given the current volume-based procurement (“VBP”) program in China, it is expected that the competitive edge of imported originator products will be gradually diminishing when the localised affordable generics become more widely available. The Group will continue to seek the opportunity to develop the domestic generic versions to pave the way for the Group’s long-term prosperity. In the ensuing year, the Group will seek to reach new benchmarks in the sales of newly approved products to gradually fill the revenue gap.

展望

踏入二零二二年末，本集團認為在COVID疫情、地緣政治緊張局勢以及通脹攀升等若干外在因素不明朗的情況下，營商環境將持續艱困；本集團同時預料，中國一方面推動藥業發展，另一方面要確保為普羅病人提供可負擔的大眾化藥物，此一未決難題將使業界繼續面對藥價受壓的嚴峻挑戰。本集團將密切監察相關影響，繼續實施嚴緊的成本控制，量入為出。

《可益能》[®]十多年來一直為本集團的旗艦產品，其許可協議的屆滿，標誌着本集團一個新時代的開始。儘管如此，鑑於中國目前實行藥品集中帶量採購（「藥品集採」）計劃，預期原廠進口產品的競爭優勢將逐步減退，而價格合理的國產仿製藥則會更為普及。本集團將繼續尋求開發國產仿製藥的機會，為本集團的長遠發展鋪橋搭路。來年，本集團將致力於實現新批產品的新銷售基準，逐步填補收益缺口。

Furthermore, the Group has implemented a series of measures to adapt to the “new normal” and to emphasis efficiency at every step of the value chain, particularly in key areas such as sales and R&D, after taking the present conditions into consideration, and the effect has continued to show.

The Group will continue to adopt prudent business and financial strategies to strengthen its foundation. The Group firmly believes that all these works to be done will eventually drive growth therefor and will eventually create more value to reward its shareholders, staff and customers for their support.

再者，於考慮到當前環境後，本集團已實施一連串措施適應「新常態」，價值鏈中的每一個環節（尤其是銷售及研發等關鍵流程）均強調效率，成效亦已持續展現。

本集團將繼續採取審慎的業務及財務政策，以期鞏固基礎。本集團深信，上述各項工作將可推動增長，最終為鼎力支持本集團的股東、員工及客戶創造更高價值。

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

簡明綜合損益表

For the three months and nine months ended 30 September 2022

截至二零二二年九月三十日止三個月及九個月

		For the three months ended 30 September 截至九月三十日止三個月		For the nine months ended 30 September 截至九月三十日止九個月		
		2022	2021	2022	2021	
		二零二二年	二零二一年	二零二二年	二零二一年	
Notes		HK\$'000	HK\$'000	HK\$'000	HK\$'000	
附註		千港元	千港元	千港元	千港元	
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	
		(未經審核)	(未經審核)	(未經審核)	(未經審核)	
Revenue	收益	3	387,016	368,335	1,036,182	952,387
Cost of sales	銷售成本		(144,693)	(120,085)	(374,381)	(317,591)
Gross profit	毛利		242,323	248,250	661,801	634,796
Other income	其他收入	4	19,490	19,690	65,192	84,628
Other gains and losses, net	其他收益及虧損淨額		(4,415)	(2,310)	(9,642)	2,090,956
Selling and distribution expenses	銷售及分銷費用		(92,906)	(94,745)	(269,121)	(258,863)
Administrative expenses	行政費用		(58,253)	(92,077)	(169,328)	(216,278)
Net (provision for)/reversal of expected credit losses on financial assets	財務資產預期信貸虧損(撥備)/撥回淨額		(1,710)	598	(1,963)	179
Research and development expenses	研究及開發費用		(50,263)	(67,549)	(166,853)	(180,448)
Profit from operations	經營溢利		54,266	11,857	110,086	2,154,970
Finance costs	財務成本		(1,794)	(1,752)	(5,293)	(4,275)
Share of results of associates	分佔聯營公司業績		(227)	(62)	(753)	(3,373)
Profit before taxation	除稅前溢利		52,245	10,043	104,040	2,147,322
Taxation	稅項	5	(20,630)	1,041	(45,343)	(2,336)
Profit for the period	本期間溢利		31,615	11,084	58,697	2,144,986
Attributable to:	下列人士應佔：					
Owners of the Company	本公司擁有人		34,224	13,843	62,684	2,169,043
Non-controlling interests	非控股權益		(2,609)	(2,759)	(3,987)	(24,057)
			31,615	11,084	58,697	2,144,986
			HK cents	HK cents	HK cents	HK cents
			港仙	港仙	港仙	港仙
Earnings per share:	每股盈利：					
Basic	基本	7	5.81	2.35	10.65	368.52
Diluted	攤薄	7	5.81	2.35	10.65	368.34

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the three months and nine months ended 30
September 2022

簡明綜合損益及其他全面 收益表

截至二零二二年九月三十日止三個月及
九個月

		For the three months ended 30 September		For the nine months ended 30 September	
		截至九月三十日止三個月		截至九月三十日止九個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Profit for the period	本期間溢利	31,615	11,084	58,697	2,144,986
Other comprehensive (expense)/ income:	其他全面(開支)/收益：				
Items that may be reclassified subsequently to profit or loss:	其後可能重新分類至損益之 項目：				
- Exchange differences on translation of financial statements of overseas subsidiaries	- 換算海外附屬公司財務 報表之匯兌差額	(71,548)	9,531	(121,359)	21,563
- Share of other comprehensive income of associates	- 分佔聯營公司之其他全面 收益	-	-	-	46
Item that will not be reclassified subsequently to profit or loss:	其後不會重新分類至損益之 項目：				
- Fair value changes of financial assets at fair value through other comprehensive income	- 按公平值透過其他全面收益 列賬之財務資產之公平值 變動	(201,277)	(602,504)	(493,142)	(1,384,331)
Other comprehensive expense for the period, net of tax	本期間其他全面開支，已扣除 稅項	(272,825)	(592,973)	(614,501)	(1,362,722)
Total comprehensive (expense)/ income for the period	本期間全面(開支)/收益總額	(241,210)	(581,889)	(555,804)	782,264
Total comprehensive (expense)/ income for the period attributable to:	下列人士應佔本期間全面 (開支)/收益總額：				
Owners of the Company	本公司擁有人	(238,041)	(578,825)	(549,039)	810,978
Non-controlling interests	非控股權益	(3,169)	(3,064)	(6,765)	(28,714)
		(241,210)	(581,889)	(555,804)	782,264

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the nine months ended 30 September 2022

簡明綜合權益變動表

截至二零二二年九月三十日止九個月

	Attributable to the owners of the Company 本公司擁有人應佔								Attributable to non-controlling interests		Total 總計	
	Share capital 股本	Share premium 股份溢價	Merger difference 合併差額	Share-based	Other	Investments	Exchange reserve 匯兌儲備	Retained profits 保留溢利	Sub-total 小計	Non-controlling interests 應佔		
				compensation reserve 酬金儲備	reserves 其他儲備	revaluation reserve 儲備						
	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元		
At 1 January 2022 (audited)	於二零二二年一月一日 (經審核)	29,442	720,091	9,200	55,964	65,302	(1,948,815)	22,838	3,510,556	2,464,578	(73,416)	2,391,162
Employee share option benefits	僱員購股權福利	-	-	-	9,382	-	-	-	-	9,382	-	9,382
Profit/(loss) for the period	本期間溢利/(虧損)	-	-	-	-	-	-	-	62,684	62,684	(3,987)	58,697
Other comprehensive expense for the period	本期間其他全面開支	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences on translation of financial statements of overseas subsidiaries	- 換算海外附屬公司財務報表之匯兌差額	-	-	-	-	-	(120,628)	-	-	(120,628)	(731)	(121,359)
- Fair value changes of financial assets at fair value through other comprehensive income	- 按公平值透過其他全面收益列賬之財務資產之公平值變動	-	-	-	-	(491,095)	-	-	(491,095)	(491,095)	(2,047)	(493,142)
Total comprehensive (expense)/income for the period	本期間全面(開支)/收益總額	-	-	-	-	(491,095)	(120,628)	-	62,684	(549,039)	(6,765)	(555,804)
2021 final dividend paid	已付二零二一年末期股息	-	-	-	-	-	-	-	(18,254)	(18,254)	-	(18,254)
2022 interim dividend paid	已付二零二二年中期股息	-	-	-	-	-	-	-	(5,888)	(5,888)	-	(5,888)
At 30 September 2022 (unaudited)	於二零二二年九月三十日 (未經審核)	29,442	720,091	9,200	65,346	65,302	(2,439,910)	(97,790)	3,549,098	1,900,779	(80,181)	1,820,598

Attributable to the owners of the Company
本公司擁有人應佔

		Share capital	Share premium	Merger difference	Share-based compensation reserve	Other reserves	Investments revaluation reserve	Exchange reserve	Retained profits	Sub-total	Attributable to non-controlling interests	Total
		股本	股份溢價	合併差額	以股份支付之酬金儲備	其他儲備	儲備	匯兌儲備	保留溢利	小計	應佔	總計
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元	千港元
At 1 January 2021 (audited)	於二零二一年一月一日 (經審核)	29,406	714,813	9,200	40,847	65,228	(254,155)	(14,843)	1,559,299	2,149,795	(34,417)	2,115,378
Employee share option benefits	僱員購股權福利	-	-	-	13,464	-	-	-	-	13,464	-	13,464
Exercise of share options	行使購股權	36	5,278	-	(1,771)	-	-	-	-	3,543	-	3,543
Share of reserve of an associate	分佔一間聯營公司儲備	-	-	-	-	28	-	-	-	28	-	28
Profit/(loss) for the period	本期間溢利/(虧損)	-	-	-	-	-	-	-	2,169,043	2,169,043	(24,057)	2,144,986
Other comprehensive income/(expense) for the period	本期間其他全面收益/(開支)	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences on translation of financial statements of overseas subsidiaries	- 換算海外附屬公司財務報表之匯兌差額	-	-	-	-	-	-	21,453	-	21,453	110	21,563
- Share of other comprehensive income of associates	- 分佔聯營公司之其他全面收益	-	-	-	-	46	-	-	-	46	-	46
- Fair value changes of financial assets at fair value through other comprehensive income	- 按公平值透過其他全面收益列賬之財務資產之公平值變動	-	-	-	-	-	(1,379,564)	-	-	(1,379,564)	(4,767)	(1,384,331)
Total comprehensive income/(expense) for the period	本期間全面收益/(開支)總額	-	-	-	-	46	(1,379,564)	21,453	2,169,043	810,978	(28,714)	782,264
2020 final dividend paid	已付二零二零年末期股息	-	-	-	-	-	-	-	(18,254)	(18,254)	-	(18,254)
At 30 September 2021 (unaudited)	於二零二一年九月三十日 (未經審核)	29,442	720,091	9,200	52,540	65,302	(1,633,719)	6,610	3,710,088	2,959,554	(63,131)	2,896,423

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the nine months ended 30 September 2022

未經審核簡明綜合財務報表附註

截至二零二二年九月三十日止九個月

1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standards (“**HKASs**”) issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”) as well as with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

2. PRINCIPAL ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values as appropriate.

The unaudited condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual financial statements for the year ended 31 December 2021.

The accounting policies and methods of computation used in preparing the unaudited condensed consolidated financial statements for the nine months ended 30 September 2022 are consistent with those used in the Group’s annual financial statements for the year ended 31 December 2021 except as described below.

1. 編製基準

未經審核簡明綜合財務報表乃按照香港會計師公會頒佈之香港會計準則及香港聯合交易所有限公司證券上市規則附錄十六之適用披露規定編製。

2. 主要會計政策

未經審核簡明綜合財務報表乃按歷史成本基準編製，惟若干財務工具按公平值計量（視適當情況而定）。

未經審核簡明綜合財務報表不包括須於全年財務報表提供之所有資料及披露事項，並應與本集團截至二零二一年十二月三十一日止年度之全年財務報表一併閱讀。

編製截至二零二二年九月三十日止九個月之未經審核簡明綜合財務報表所用之會計政策及計算方法與本集團截至二零二一年十二月三十一日止年度之全年財務報表所用者一致，惟下述者除外。

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

In the current reporting period, the Group has applied the following amendments to HKFRS issued by the HKICPA for the first time which are mandatorily effective for the annual periods beginning on or after 1 January 2022 for the preparation of the Group's unaudited condensed consolidated financial statements. HKFRS comprise Hong Kong Financial Reporting Standards; HKASs; and HK (IFRIC) Interpretations, HK Interpretations and HK (SIC) Interpretations.

Amendments to HKAS 16	Property, Plant and Equipment – Proceeds before Intended Use
Amendments to HKAS 37	Onerous Contracts – Cost of Fulfilling a Contract
Amendments to HKFRS 3	Reference to the Conceptual Framework
Amendments to HKFRS 16	COVID-19-Related Rent Concessions beyond 30 June 2021
Amendments to HKFRSs	Annual Improvements to HKFRSs 2018–2020

The application of these amendments to HKFRS has had no material effect on the amounts reported in these unaudited condensed consolidated financial statements and/or disclosures set out in these unaudited condensed consolidated financial statements.

2. 主要會計政策(續)

於本報告期間，本集團就編製未經審核簡明綜合財務報表首次應用香港會計師公會所頒佈於二零二二年一月一日或之後開始之年度期間強制生效之下列香港財務報告準則之修訂。香港財務報告準則包括香港財務報告準則；香港會計準則；以及香港(國際財務報告詮釋委員會)詮釋、香港詮釋及香港(準則詮釋委員會)詮釋。

香港會計準則第16號之修訂	物業、廠房及設備 — 作擬定用途前 之所得款項
香港會計準則第37號之修訂	虧損合約—履行 合約之成本
香港財務報告準則第3號之修訂	對概念框架之提述
香港財務報告準則第16號之修訂	於二零二一年 六月三十日後之 COVID-19相關 租金優惠
香港財務報告準則之修訂	香港財務報告準則 二零一八年至 二零二零年之 年度改進

應用該等香港財務報告準則之修訂對本未經審核簡明綜合財務報表所呈報之金額及/或本未經審核簡明綜合財務報表所載之披露事項並無重大影響。

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

The Group has not early applied the following new and amendments to HKFRS that have been issued but are not yet effective:

HKFRS 17	Insurance Contracts and the related Amendments ¹
Amendments to HKAS 1	Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020) ¹
Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies ¹
Amendments to HKAS 8	Definition of Accounting Estimates ¹
Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction ¹
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture ²

- ¹ Effective for annual periods beginning on or after 1 January 2023, earlier application is permitted
- ² Effective date to be determined

The Group has already commenced an assessment of the impact of these new and amendments to HKFRS but is not yet in a position to state whether these new and amendments to HKFRS would have a material impact on its results of operations and financial positions.

2. 主要會計政策(續)

本集團並無提早應用下列已頒佈但尚未生效之新增香港財務報告準則及香港財務報告準則之修訂：

香港財務報告準則第17號	保險合約及相關修訂 ¹
香港會計準則第1號之修訂	流動或非流動負債之分類及香港詮釋第5號(二零二零年)之相關修訂 ¹
香港會計準則第1號及香港財務報告準則實務聲明第2號之修訂	會計政策披露 ¹
香港會計準則第8號之修訂	會計估計定義 ¹
香港會計準則第12號之修訂	與一項單一交易產生之資產及負債有關之遞延稅項 ¹
香港財務報告準則第10號及香港會計準則第28號之修訂	投資者與其聯營公司或合營企業之間之資產出售或注資 ²

- ¹ 於二零二三年一月一日或之後開始之年度期間生效，可提早應用
- ² 生效日期待定

本集團已開始評估該等新香港財務報告準則及香港財務報告準則之修訂之影響，但尚無法說明該等新香港財務報告準則及香港財務報告準則之修訂會否對本集團之經營業績及財務狀況造成重大影響。

3. REVENUE

The principal activities of the Group are the developing, manufacturing and sales and marketing of pharmaceutical products. During the period, revenue represents the net amount received and receivable for goods sold by the Group to outside customers and are recognised at point in time as follows:

Business segments

		For the three months ended 30 September		For the nine months ended 30 September	
		截至九月三十日止三個月		截至九月三十日止九個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Proprietary and generic products	專利及仿製產品	144,946	145,766	397,033	395,401
Licensed-in products	引進產品	242,070	222,569	639,149	556,986
		387,016	368,335	1,036,182	952,387

Geographical segments

During the three months and nine months ended 30 September 2022 and 2021, more than 90% of the Group's revenue was derived from activities conducted in the People's Republic of China (the "PRC"), no geographical segmental information is presented.

3. 收益

本集團的主要業務為開發、製造、銷售及推廣藥品。期內，收益指本集團向外部客戶出售貨品的已收及應收款項淨額，按時間點確認如下：

業務分部

地區分部

於截至二零二二年及二零二一年九月三十日止三個月及九個月，本集團逾90%收益源自於中華人民共和國（「中國」）進行之業務，故此並無呈列地區分部資料。

4. OTHER INCOME

4. 其他收入

		For the three months ended 30 September		For the nine months ended 30 September	
		截至九月三十日止三個月		截至九月三十日止九個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Interest income on:	下列各項之利息				
	收入:				
Bank deposits	銀行存款	621	535	1,804	1,927
Financial assets at fair value through profit or loss	按公平值透過損益 列賬之財務資產	-	-	-	83
Advance to associates	墊付予聯營公司之 款項	-	868	-	2,447
Total interest income	利息收入總額	621	1,403	1,804	4,457
Development and government grants	開發及政府補助	623	2,443	17,717	13,058
Rental and utilities income	租金及公共服務收入	4,301	3,801	10,298	8,721
Research and development service income	研究及開發服務收入	9,845	8,205	29,065	53,209
Sundry income	雜項收入	4,100	3,838	6,308	5,183
		19,490	19,690	65,192	84,628

The Group received the development grants from local government as recognition of the Group's performance and development of high-technology pharmaceutical products.

本集團收到地方政府為認可本集團表現及開發高新科技藥品而授予之開發補助。

5. TAXATION

5. 稅項

		For the three months ended 30 September 截至九月三十日止三個月		For the nine months ended 30 September 截至九月三十日止九個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Current tax	即期稅項				
Hong Kong Profits Tax	香港利得稅	7,067	(7,120)	19,503	8,082
PRC Enterprise Income Tax	中國企業所得稅	(362)	1,993	-	1,993
		6,705	(5,127)	19,503	10,075
Under/(over) provision in prior years	過往年度撥備不足/ (超額撥備)				
Hong Kong Profits Tax	香港利得稅	5,376	171	5,376	171
PRC Enterprise Income Tax	中國企業所得稅	-	(1)	-	(531)
		5,376	170	5,376	(360)
Deferred tax	遞延稅項				
Origination and reversal of temporary differences	產生及撥回暫時 差額	8,549	3,916	20,464	(7,379)
		20,630	(1,041)	45,343	2,336

Hong Kong Profits Tax for the three and nine months ended 30 September 2022 is calculated at 8.25% (three and nine months ended 30 September 2021: 8.25%) on the first HK\$2 million of the estimated assessable profits and at 16.5% (three and nine months ended 30 September 2021: 16.5%) on the estimated assessable profits above HK\$2 million according to the two-tiered profits tax rates regime.

Tax arising in the PRC is calculated at the tax rates prevailing in the PRC. Taxation arising in other jurisdictions is calculated at the tax rate prevailing in the relevant jurisdictions.

按照利得稅兩級制，截至二零二二年九月三十日止三個月及九個月之香港利得稅就首2百萬港元估計應課稅溢利按8.25%（截至二零二一年九月三十日止三個月及九個月：8.25%）及就2百萬港元以上估計應課稅溢利按16.5%（截至二零二一年九月三十日止三個月及九個月：16.5%）計算。

於中國產生之稅項按中國現行稅率計算。於其他司法權區產生之稅項按有關司法權區之現行稅率計算。

6. DIVIDENDS

An interim dividend for the six months ended 30 June 2022 of HK\$0.010 per share, totalling approximately HK\$5,888,000 (six months ended 30 June 2021: HK\$0.030 per share, totalling approximately HK\$17,665,000) was declared on 26 August 2022 and paid on 27 September 2022.

The board of directors does not recommend the payment of other interim dividend for the nine months ended 30 September 2022 (nine months ended 30 September 2021: Nil).

7. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

	For the three months ended 30 September		For the nine months ended 30 September	
	截至九月三十日止三個月		截至九月三十日止九個月	
	2022	2021	2022	2021
	二零二二年	二零二一年	二零二二年	二零二一年
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
	千港元	千港元	千港元	千港元
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	(未經審核)	(未經審核)	(未經審核)	(未經審核)
Earnings:	盈利:			
Net profit attributable to the owners of the Company for the purpose of basic and diluted earnings per share	就計算每股基本及攤薄盈利而言之本公司擁有人應佔純利			
	34,224	13,843	62,684	2,169,043

6. 股息

本公司於二零二二年八月二十六日宣派並於二零二二年九月二十七日派付截至二零二二年六月三十日止六個月之中期股息每股0.010港元(合計約5,888,000港元)(截至二零二一年六月三十日止六個月:每股0.030港元(合計約17,665,000港元))。

董事會不建議派付截至二零二二年九月三十日止九個月的其他中期股息(截至二零二一年九月三十日止九個月:無)。

7. 每股盈利

本公司擁有人應佔每股基本及攤薄盈利乃基於下列數據計算:

7. EARNINGS PER SHARE (CONTINUED)

7. 每股盈利(續)

		For the three months ended 30 September 截至九月三十日止三個月		For the nine months ended 30 September 截至九月三十日止九個月	
		2022	2021	2022	2021
		二零二二年	二零二一年	二零二二年	二零二一年
		Share(s)'000	Share(s)'000	Share(s)'000	Share(s)'000
		千股	千股	千股	千股
		(unaudited)	(unaudited)	(unaudited)	(unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Number of shares:	股份數目：				
Weighted average number of ordinary shares for the purpose of basic earnings per share	就計算每股基本盈利而言之普通股加權平均數	588,835	588,835	588,835	588,586
Effect of dilutive potential ordinary shares:	潛在攤薄普通股之影響：				
Options	購股權	-	195	-	282
Weighted average number of ordinary shares for the purpose of diluted earnings per share	就計算每股攤薄盈利而言之普通股加權平均數	588,835	589,030	588,835	588,868

8. RELATED PARTY TRANSACTIONS

During the reporting period, the Group entered into the following transactions with related parties. In the opinion of the directors of the Company, the following transactions arose in the ordinary course of the Group's business.

(a) Transaction with associates

8. 關聯方交易

於報告期內，本集團與關聯方進行以下交易。本公司董事認為，下列交易乃於本集團日常業務中產生。

(a) 與聯營公司之交易

For the nine months ended 30 September

截至九月三十日止九個月

		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Interest income	利息收入	-	2,447
Rental and utilities income	租金及公共服務收入	-	4,231
Research and development service income	研究及開發服務收入	-	21,798
Purchase of consumable	採購消耗品	-	2,850

8. RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Compensation of key management personnel

The remuneration of directors of the Company and other members of key management during the reporting period was as follows:

8. 關聯方交易(續)

(b) 主要管理人員之補償

報告期內，本公司董事及其他主要管理人員之薪酬如下：

		For the nine months ended 30 September	
		截至九月三十日止九個月	
		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(unaudited)
		(未經審核)	(未經審核)
Short-term employee benefits	短期僱員福利	12,819	39,292
Share-based payments	以股份支付之款項	6,515	8,343
Retirement and other post-employment benefits	退休及其他離職後福利	5,414	18,012
- Defined contribution plan	一定額供款計劃	14	12
- Retirement benefits	一退休福利	5,400	18,000
		24,748	65,647

8. RELATED PARTY TRANSACTIONS (CONTINUED)

(c) Donation to Lee's Pharmaceutical – Kanya Lee Scholarship Limited (“Kanya Lee Scholarship”)

During the nine months ended 30 September 2022, a total of HK\$1,900,000 (nine months ended 30 September 2021: HK\$1,250,000) was donated to Kanya Lee Scholarship. Ms. Leelalertsuphakun Wanee and Ms. Lee Siu Fong, directors of the Company, are also members of key management of Kanya Lee Scholarship and Kanya Lee Scholarship is considered as a related party to the Group.

8. 關聯方交易(續)

(c) 向李氏大藥廠－李杜靜芳 獎學金有限公司(「李杜靜 芳獎學金」)作出捐獻

於截至二零二二年九月三十日止九個月，向李杜靜芳獎學金捐獻合共1,900,000港元(截至二零二一年九月三十日止九個月：1,250,000港元)。本公司董事李燁妮女士及李小芳女士亦為李杜靜芳獎學金之主要管理層成員，而李杜靜芳獎學金被視為本集團之關聯方。

9. CAPITAL COMMITMENTS

9. 資本承擔

		30 September 2022	31 December 2021
		二零二二年 九月三十日	二零二一年 十二月三十一日
		HK\$'000	HK\$'000
		千港元	千港元
		(unaudited)	(audited)
		(未經審核)	(經審核)
Capital commitments contracted for in respect of:	已就下列各項訂約之資本承擔：		
Financial assets at fair value through other comprehensive income	按公平值透過其他全面收益列賬之財務資產	24,505	39,119
Intangible assets – license fee and development cost	無形資產 – 專利費及開發成本	125,790	125,162
Property, plant and equipment	物業、廠房及設備	77,073	85,567
		227,368	249,848

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities during the nine months ended 30 September 2022.

DIVIDEND

The Board does not recommend payment of dividend for the nine months ended 30 September 2022 (nine months ended 30 September 2021: Nil).

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 17 November 2022

As at the date of this report, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive Directors; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl, are independent non-executive Directors.

購買、出售或贖回上市證券

於截至二零二二年九月三十日止九個月，本公司或其任何附屬公司並無購買、出售或贖回本公司任何上市證券。

股息

董事會不建議派付截至二零二二年九月三十日止九個月的股息(截至二零二一年九月三十日止九個月：無)。

承董事會命
李氏大藥廠控股有限公司
主席
李小芳

香港，二零二二年十一月十七日

於本報告日期，李小芳女士(主席)及李熾妮女士為執行董事；李小平博士及James Charles Gale先生為非執行董事；而陳友正博士、林日昌先生及詹華強博士為獨立非執行董事。

